1. Home
  2. VERU vs AAME Comparison

VERU vs AAME Comparison

Compare VERU & AAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

SELL

Current Price

$2.92

Market Cap

48.2M

Sector

Health Care

ML Signal

SELL

Logo Atlantic American Corporation

AAME

Atlantic American Corporation

HOLD

Current Price

$1.77

Market Cap

41.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERU
AAME
Founded
1971
1968
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Life Insurance
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
48.2M
41.4M
IPO Year
1996
1995

Fundamental Metrics

Financial Performance
Metric
VERU
AAME
Price
$2.92
$1.77
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$22.50
N/A
AVG Volume (30 Days)
5.2M
14.0K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
0.81%
EPS Growth
N/A
N/A
EPS
N/A
0.22
Revenue
$16,296,958.00
$188,227,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.50
Revenue Growth
N/A
0.77
52 Week Low
$0.36
$1.59
52 Week High
$7.33
$3.71

Technical Indicators

Market Signals
Indicator
VERU
AAME
Relative Strength Index (RSI) 52.97 35.54
Support Level $2.15 $1.59
Resistance Level $3.68 $3.16
Average True Range (ATR) 0.67 0.11
MACD -0.01 0.01
Stochastic Oscillator 15.52 28.81

Price Performance

Historical Comparison
VERU
AAME

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.

Share on Social Networks: